Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Blood (2024) 144 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2024-199336

Published: 2024

Journal Articles

MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Mark J Althoff, Mohd Minhajuddin, Brett M Stevens, Austin E Gillen, Regan Miller, Ana Vujovic, Sweta B Patel, William Showers, Stephanie Gipson, Monika Dzieciatkowska, Jana M Ellegast, Tristen Wright, Kimberly Stegmaier, Joseph T Opferman, Craig T Jordan

Blood (2024) 144 (Supplement 1): 39.

https://doi.org/10.1182/blood-2024-206516

Published: 2024

Journal Articles

Distinct Roles for mTOR- and CDK1-Dependent Translation in FLT3-Mutated AML Cell Survival

Daniela R Ortiz Chavez, Hae J Park, Mark A Gregory, Craig T Jordan, James V DeGregori

Blood (2024) 144 (Supplement 1): 5795.

https://doi.org/10.1182/blood-2024-211569

Published: 2024

Journal Articles

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan Gutman, Andrew Kent, Diana Abbott, Connor Sohalski, Jessica Dell-Martin, Ayele Belachew, Brett M Stevens, Craig T Jordan, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2024-202839

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment

Christina M Kaszuba, Cameron D Baker, Benjamin J Rodems, Sonali Sharma, Jane L. Liesveld, Laura M. Calvi, Michael W. Becker, Craig T Jordan, John M. Ashton, Jeevisha Bajaj

Blood (2024) 144 (Supplement 1): 1302.

https://doi.org/10.1182/blood-2024-210878

Published: 2024

Journal Articles

CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia

Haley M. Simpson, Amanda Novak, Catherine Danis, Michael Yarnell, Phoebe Duong, Brett M Stevens, Craig T Jordan, M. Eric Kohler

Blood (2024) 144 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2024-205683

Published: 2024

Journal Articles

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Hunter Tolison, Cassandra Duarte, Glen Peterson, Grace N Bosma, Diana Abbott, Gemlyn George, Daniel Pollyea, Craig T. Jordan, Maria L Amaya

Blood (2023) 142 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2023-179669

Published: 2023

Journal Articles

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan A Gutman, Connor Sohalski, Jennifer Tobin, Austin E Gillen, Anagha Inguva Sheth, Brett M Stevens, Clayton Smith, Craig T. Jordan, Daniel A. Pollyea

Blood (2023) 142 (Supplement 1): 2914.

https://doi.org/10.1182/blood-2023-182966

Published: 2023

Journal Articles

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Blood (2023) 142 (Supplement 1): 588.

https://doi.org/10.1182/blood-2023-188285

Published: 2023

Journal Articles

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Marc Schwartz, Jonathan A Gutman, Christine M. McMahon, Maria L Amaya, Daniel A. Pollyea, Matthew Witkowski, Mohd Minhajuddin, Clayton Smith, Craig T. Jordan

Blood (2023) 142 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2023-188298

Published: 2023

Journal Articles

Consolidation with Ponatinib Plus Sequential Blinatumomab and Chemotherapy after Low Intensity Dasatinib-Based Induction in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Outcomes from a Single Institution

Marc Schwartz, Christine M. McMahon, Maria L Amaya, Matthew Witkowski, Daniel A. Pollyea, Jonathan A Gutman, Mohd Minhajuddin, Clayton Smith, Craig T. Jordan

Blood (2023) 142 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2023-188118

Published: 2023

Journal Articles

A Novel CD64 CAR-T Therapy for the Treatment of Monocytic Acute Myeloid Leukemia

Haley M. Simpson, Brett M Stevens, Craig T. Jordan, M. Eric Kohler

Blood (2023) 142 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2023-182123

Published: 2023

Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Blood (2022) 140 (Supplement 1): 3275–3276.

https://doi.org/10.1182/blood-2022-157802

Published: 2022

Journal Articles

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Mohd Minhajuddin, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Nicholas Miltgen, Ji Yuan, Amy Treece, Jonathan A. Gutman, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6274–6275.

https://doi.org/10.1182/blood-2022-167856

Published: 2022

Journal Articles

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Anagha Inguva, Krysta L. Engel, Hunter Tolison, Mark J Althoff, Shanshan Pei, Maria L. Amaya, Anna Krug, Mohammad Minhajuddin, Courtney L Jones, Austin E. Gillen, Monica Ransom, Sarah Staggs, Daniel A. Pollyea, Clayton Smith, Brett M. Stevens, Craig T. Jordan

Blood (2022) 140 (Supplement 1): 5922–5923.

https://doi.org/10.1182/blood-2022-167787

Published: 2022

Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6185–6186.

https://doi.org/10.1182/blood-2022-170168

Published: 2022

Journal Articles

Targeting Microenvironmental Signals in Myeloid Malignancies

Benjamin Rodems, Sonali Sharma, Takashi Ito, Craig T Jordan, Michael W. Becker, Laura M. Calvi, John M. Ashton, Jeevisha Bajaj

Blood (2022) 140 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2022-163601

Published: 2022

Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon

Blood (2022) 140 (Supplement 1): 9163–9164.

https://doi.org/10.1182/blood-2022-171064

Published: 2022

Journal Articles

Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

Mohd Minhajuddin, Amanda C. Winters, Marc Schwartz, Daniel A. Pollyea, Craig T Jordan

Blood (2022) 140 (Supplement 1): 5986–5987.

https://doi.org/10.1182/blood-2022-169167

Published: 2022

NARROW

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Distinct Roles for mTOR- and CDK1-Dependent Translation in FLT3-Mutated AML Cell Survival

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment

CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Consolidation with Ponatinib Plus Sequential Blinatumomab and Chemotherapy after Low Intensity Dasatinib-Based Induction in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Outcomes from a Single Institution

A Novel CD64 CAR-T Therapy for the Treatment of Monocytic Acute Myeloid Leukemia

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Targeting Microenvironmental Signals in Myeloid Malignancies

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only